Akebia Therapeutics (AKBA) Misses Q4 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Akebia Announces Fourth Quarter and Full-Year 2015 Financial Results
March 14, 2016 4:05 PM EDT-Company to Host Conference Call at 4:30 PM Eastern Time-
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF), today announced financial results for the fourth quarter and full year ended December 31, 2015.
During 2015, we successfully executed all of our clinical and corporate objectives and we are well-positioned to build on this momentum in 2016, stated John P. Butler, President and Chief Executive Officer of Akebia. We have continued to demonstrate the therapeutic potential... More
